Increasing tetrahydrobiopterin in cardiomyocytes adversely affects cardiac redox state and mitochondrial function independently of changes in NO production

Free Radical Biology & Medicine
Savitha SethumadhavanJeannette Vasquez-Vivar

Abstract

Tetrahydrobiopterin (BH4) represents a potential strategy for the treatment of cardiac remodeling, fibrosis and/or diastolic dysfunction. The effects of oral treatment with BH4 (Sapropterin™ or Kuvan™) are however dose-limiting with high dose negating functional improvements. Cardiomyocyte-specific overexpression of GTP cyclohydrolase I (mGCH) increases BH4 several-fold in the heart. Using this model, we aimed to establish the cardiomyocyte-specific responses to high levels of BH4. Quantification of BH4 and BH2 in mGCH transgenic hearts showed age-based variations in BH4:BH2 ratios. Hearts of mice (<6 months) have lower BH4:BH2 ratios than hearts of older mice while both GTPCH activity and tissue ascorbate levels were higher in hearts of young than older mice. No evident changes in nitric oxide (NO) production assessed by nitrite and endogenous iron-nitrosyl complexes were detected in any of the age groups. Increased BH4 production in cardiomyocytes resulted in a significant loss of mitochondrial function. Diminished oxygen consumption and reserve capacity was verified in mitochondria isolated from hearts of 12-month old compared to 3-month old mice, even though at 12 months an improved BH4:BH2 ratio is established. Accumulatio...Continue Reading

References

Dec 19, 1995·Proceedings of the National Academy of Sciences of the United States of America·H NarA Bacher
Aug 5, 1998·Proceedings of the National Academy of Sciences of the United States of America·J Vásquez-VivarK A Pritchard
Feb 6, 2002·Free Radical Biology & Medicine·Kantilal B PatelSteven A Everett
Nov 7, 1996·Chemical Reviews·T. Joseph Kappock, John P. Caradonna
Jul 30, 2005·The Biochemical Journal·Chantal Capeillere-BlandinDaniel Mansuy
Jul 19, 2008·Free Radical Biology & Medicine·Jeannette Vásquez-VivarGalen M Pieper
Aug 8, 2008·Proceedings of the National Academy of Sciences of the United States of America·John W ElrodDavid J Lefer
Oct 7, 2008·American Journal of Physiology. Heart and Circulatory Physiology·Irina A IonovaGalen M Pieper
Jun 17, 2009·Proceedings of the National Academy of Sciences of the United States of America·Tracy A PrimeMichael P Murphy
Sep 11, 2009·The Biochemical Journal·Bradford G HillVictor M Darley-Usmar
Oct 3, 2009·Annals of Neurology·Jeannette Vásquez-VivarSidhartha Tan
Apr 27, 2010·American Journal of Physiology. Heart and Circulatory Physiology·Irina A IonovaGalen M Pieper
Aug 3, 2010·Current Cardiology Reviews·David J KaczorowskiTimothy R Billiar
Aug 17, 2011·Journal of Molecular and Cellular Cardiology·Joanna Hammond, Jean-Luc Balligand
Aug 27, 2011·The Biochemical Journal·Ernst R WernerBeat Thöny
Oct 8, 2011·Journal of Molecular and Cellular Cardiology·Euy-Myoung JeongSamuel C Dudley
May 1, 2012·The Journal of Biological Chemistry·Savitha SethumadhavanJozef Lazar
Aug 9, 2012·Antioxidants & Redox Signaling·Ricardo CarnicerDavid A Kass
May 28, 2013·Free Radical Biology & Medicine·Jennifer WhitsettJeannette Vasquez-Vivar
Sep 23, 2014·FEBS Letters·Feng XuHiroshi Ichinose

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.